Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis

Abstract

The importance of apolipoprotein E (ApoE) and myeloperoxidase (MPO) genotypes in the clinical characteristics of multiple sclerosis (MS) has been recently emphasized. In a large group of Polish patients we have tested the hypothesis that polymorphism in ApoE and MPO genes may influence the course of the disease. G enotypes were determined in 117 MS patients (74 females and 43 males; 99 sporadic and 18 familial cases) with mean EDSS of 3.6, mean age of 44.1 years, mean duration of the disease 12.8 years and mean onset of MS at 31.2 years, and in 100 healthy controls. The relationship between ApoE and MPO genes’ polymorphism and the MS activity as well as the defect of remyelination (diffuse demyelination) and brain atrophy on MRI were analysed. The ApoE o4 allele was not related to the disease course or the ApoE o2 to the intensity of demyelination on MRI. The genotype MPO G/G was found in all familial MS and in 57% (56/99) of sporadic cases. This genotype was also related to more pronounced brain atrophy on MRI. The MPO G/G subpopulation was characterized by a significantly higher proportion of patients with secondary progressive MS (PB- 0.05) and by a higher value of EDSS. A ccording to our results the MPO G allele is frequently found (in 96% of cases) among Polish patients with MS. More severe nervous tissue damage in the MPO G/G form can be explained by the mechanism of accelerated oxidative stress. It seems that MPO G/G genotype may be one of the genetic factors influencing the progression rate of disability in MS patients.

Keywords

apolipoprotein E genes multiple sclerosis myeloperoxidase polymorphism

Get full access to this article

View all access options for this article.

References

Miller JR. Multiple sclerosis. In Rolland LP ed. Merritt’s neurology, tenth edition. Philadelphia, PA: Lippincott Williams & Wilkins , 2000: 773-792.

Kantarci OH , de Andrade M , Weinshenker BG. Identifying disease modifying genes in multiple sclerosis . J Neuroimmunol 2002; 123: 144-159 .

Haines JL , Ter-Minassian M , Bazyk A. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility. The Multiple Sclerosis Genetics Group . Nat Genet 1996; 13: 469-471 .

Barcellos LF , Thomson G , Carrington M , Schafer J , Begovich AB , Lin P et al. Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis . JAMA 1997; 278: 1256-1261 .

Sawcer S , Maranian M , Setakis E , Curwen V , Akesson E , Hensiek A et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility . Brain 2002; 125: 1337-1347 .

Carlin C , Murray L , Graham D , Doyle D , Nicoli J. Involvement of apolipoprotein E in multiple sclerosis: absence of remyeli-nation associated with possession of the ApoE o2 allele . J Neuropathol Exp Neurol 2000; 59: 361-376 .

Kantarci OH , Atkinson EJ , Hebrink DD , McMurray C , Weinshenker BG. Association of am myeloperoxidase promoter polymorphism with multiple sclerosis . J Neuroimmunol 2000; 105: 189-194 .

McDonald I , Compston A , Edan G , Goodkin D , Hartung HP , Lublin F et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

Chapman J , Estupinana J , Asherow A. A simple and efficient method for apolipoprotein E genotype determination . Neurology 1996; 46: 1484-1485 .

10.

Reynolds WF. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer’s disease . Exp Neurol 1999; 155: 31-41 .

11.

Kelly MA , Cavan DA , Penny MA , Mijovic CH , Jenkins D , Morrisey S et al. The influence of HLA-DR and DQ alleles on progression in multiple sclerosis following the clinically isolated syndrome . Hum Immunol 1993; 37: 185-191 .

12.

Hauser SL , Oksenberg JR , Lincoln R , Garovoy J , Beck RW , Cole SR et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group . Neurology 2000; 54: 1859-1861 .

13.

Masterman T , Zhang Z , Hellgren D , Salter H , Anvret M , Lilius L et al. ApoE genotypes and disease severity in multiple sclerosis . Mult Scler 2002; 8: 98-103 .

14.

Fazekas F , Strasser-Fuchs S , Kolegger H , Berger T , Kristoferitsch W , Schmidt H et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis . Neurology 2001; 57: 853-857 .

15.

Becker KG , Simon RM , Bailey-Wilson JE , Freidlin B , Biddison WE , McFarland HF et al. ApoE genotype is a major predictor of long-term progression disability in MS . Neurology 2001; 57: 2148-2149 .

16.

Chapman J , Vinokurov S , Achiron A , Karussis DM , Mitosek-Szewczyk K , Birnbaum M et al. ApoE genotype is a major predictor of long-term progression of disability in MS . Neurology 2001; 56: 312-316 .

17.

Haines JL , Schmidt S , Boylston FR , Rogala A , Rimmler JB , Vance JM et al. Follow-up analysis of the chromosome19q13 region in multiple sclerosis with single-nucleotid polymorphisms . Neurology 2001; 56: A96-A96 .

18.

Lucotte GL , The French MS Consortium. Confirmation of a gene for multiple sclerosis (MS) to chromosome 19q13.3 . Genet Couns 2002; 13: 133-138 .

19.

Weatherby SJ , Man CL , Davies MB , Fryer AA , Haq N , Strange RC et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis . Mult Scler 2000; 6: 32-36 .

20.

Schreiber K , Otura AB , Ryder LP , Madsen HO , Jorgensen OS , Svejgaard A et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) . Mult Scler 2002; 8: 295-298 .

21.

Ballerini C , Campani D , Rombola G , Gran B , Nacmias B , Pia Amato et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis . Neurosci Lett 2000; 296: 174-176 .

22.

Reunanen K , Finnila S , Laaksonen M , Sumelahti ML , Wik-strom J , Pastinen et al. Chromosome 19q13 and multiple sclerosis susceptibility in Finland: a linkage and two-stage association study . J Neuroimmunol 2002; 126: 134-142 .

23.

Haines JL , Bradford Y , Garcia ME , Reed AD , Neumeister E , Pericak-Vance et al. Multiple susceptibility loci for multiple sclerosis . Hum Mol Genet 2002; 11: 2251-2256 .

24.

Chataway J , Mander A , Robertson N , Sawcer S , Deans J , Fraser M et al. A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis . J Neuroimmunol 1999; 98: 208-213 .

25.

Saarrela J , Schoenberg Fejzo M , Chen D , Finnila S , Parkkonen M et al. Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24 . Hum Mol Genet 2002; 11: 2257-2267 .

26.

Brennan M , Gaur A , Pahuja A , Lusis AJ , Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis . J Neuroimmunol 2001; 112: 97-105 .

27.

Hoy A , Leininger-Muller B , Kutter D , Siest D , Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases . Clin Chem Lab Med 2002; 40: 2-8 .

28.

Nelisssen I , Fiten P , Vandenbroeck K , Hillert J , Olsson T , Marrosu MG et al. PECAM1, MPO and PRKARIA at chromo-some 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia . J Neuroimmunol 2000; 108: 153-159 .

29.

Nagra RM , Becher B , Tourtellotte WW , Antel JP , Gold D , Paladino T et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis . J Neuroimmunol 1997; 78: 97-107 .

30.

Pullar JM , Vissers MC , Winterbourn CC. Living with a killer: the effects of hypochlorous acid on mammalian cells . IUBMB Life 2000; 50: 259-266 .

31.

Kumagai S , Jikimoto T , Saegusa J. Pathological roles of oxidative stress in autoimmune diseases . Rinsho Byori 2003; 51: 126-132 .

32.

Mann CL , Davies MB , Boggild MD , Alldersea J , Fryer AA , Jones PW et al. Glutathione S-transferase polymorphisms in MS: their relationship to disability . Neurology 2000; 54: 552-557 .

33.

Ryu H , Lee J , Zaman K , Kubilis J , Ferrante RJ , Ross BD et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons . J Neurosci 2003; 23: 3597-3606 .